Filing Flows › Comparisons › NKTR vs ZBIO
Nektar Therapeutics vs Zenas BioPharma: NKTR and ZBIO compared
Nektar Therapeutics is the larger company: $10.1M of revenue in its latest quarter (Q2 2026) against $10.0M for Zenas BioPharma (Q3 2026).
Where the money goes: NKTR and ZBIO
Nektar Therapeutics (NKTR) · Q2 2026
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
Zenas BioPharma (ZBIO) · Q3 2026
Zenas BioPharma, Q3 2026: revenue $10.0M, net loss $109M, operating cash flow −$58.0M. The chart follows the revenue to costs, profit and cash.
| Nektar Therapeutics (NKTR) | Zenas BioPharma (ZBIO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $10.1M | $10.0M |
| Revenue growth, Y/Y | -9% | — |
| Operating margin | -417.9% | n/m |
| Net earnings | −$40.6M | −$109M |
| Net margin | -401.0% | — |
| Operating cash flow | −$75.8M | −$58.0M |
Questions
Which is bigger, Nektar Therapeutics or Zenas BioPharma?
Nektar Therapeutics is the larger company: $10.1M of revenue in its latest quarter (Q2 2026) against $10.0M for Zenas BioPharma (Q3 2026).
More: Nektar Therapeutics earnings · how Nektar Therapeutics makes money · Zenas BioPharma earnings · how Zenas BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.